Drugs that contain Eluxadoline

1. Drug name - VIBERZI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10213415 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US8609709 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US7786158 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(2 years from now)

US8691860 ALLERGAN HOLDINGS Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US9115091 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(5 years from now)

US7741356 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
May, 2029

(6 years from now)

CN101730685A ALLERGAN HOLDINGS Novel Crystals And Process Of Making 5-({[2-Amino-3-(4-Carbamoyl-2,6-Dimethyl-Phenyl)-Propionyl]-[1-(4-Phenyl-1H-Imidazol-2-Yl)-Ethyl]-Amino}-Methyl)-2-Methoxy-Benzoic Acid
Aug, 2016

(6 years ago)

CN102786476B ALLERGAN HOLDINGS Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

CN1950342B ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

CN102786476A ALLERGAN HOLDINGS New Compound As Opioid Receptor Modulator
Mar, 2025

(2 years from now)

CN1950342A ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

IN254073B ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

IN200602981P2 ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP3112352A1 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2298744A3 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2653465B1 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2573068B1 ALLERGAN HOLDINGS Process For Preparing Intermediates Of Compounds Useful As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2298744A2 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2573068B9 ALLERGAN HOLDINGS Process For Preparing Intermediates Of Compounds Useful As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP3112352B1 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2573068A1 ALLERGAN HOLDINGS Process For Preparing Intermediates Of Compounds Useful As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2653465A1 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2298744B1 ALLERGAN HOLDINGS Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP1725537B1 ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP1725537A1 ALLERGAN HOLDINGS Novel Compounds As Opioid Receptor Modulators
Mar, 2025

(2 years from now)

EP2176234B1 ALLERGAN HOLDINGS Novel Crystals And Process Of Making 5-({[2-Amino-3-(4-Carbamoyl-2,6-Dimethyl-Phenyl)-Propionyl]-[1-(4-Phenyl-1H-Imidazol-2-Yl)-Ethyl]-Amino}-Methyl)-2-Methoxy- Benzoic Acid
Jul, 2028

(5 years from now)

EP2176234A2 ALLERGAN HOLDINGS Novel Crystals And Process Of Making 5-({[2-Amino-3-(4-Carbamoyl-2,6-Dimethyl-Phenyl)-Propionyl]-[1-(4-Phenyl-1H-Imidazol-2-Yl)-Ethyl]-Amino}-Methyl)-2-Methoxy- Benzoic Acid
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700542 ALLERGAN HOLDINGS Compounds as opioid receptor modulators Mar, 2025

(2 years from now)

US8772325 ALLERGAN HOLDINGS Compounds as opioid receptor modulators Mar, 2025

(2 years from now)

US9205076 ALLERGAN HOLDINGS Compounds as opioid receptor modulators Mar, 2025

(2 years from now)

US8344011 ALLERGAN HOLDINGS Compounds as opioid receptor modulators Mar, 2025

(2 years from now)

US9364489 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid Jul, 2028

(5 years from now)

US9789125 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid Jul, 2028

(5 years from now)

US10188632 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11229627 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11090291 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11160792 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US9675587 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11007179 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.